Weiss Multi-Strategy Advisers’s Biogen BIIB Stock Holding History

Weiss Multi-Strategy Advisers’s Portfolio BIIB Stock Details BIIB Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2013 Q3	–	Sell	-5,000	Closed	-$1.08M	–	907
2013 Q2	$1.08M	Buy	+5,000	New	+$1.07M	0.03%	377

Other funds holding BIIB

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

Primecap Management Pasadena, California $127B AUM 44.11% 1-Year Est. Return

BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return

State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return

T. Rowe Price Investment Management Baltimore, Maryland $145B AUM 22.78% 1-Year Est. Return

Wellington Management Group Boston, Massachusetts $535B AUM 26.23% 1-Year Est. Return

JP Morgan Chase New York $1.56T AUM 27.86% 1-Year Est. Return

Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return

VanEck Associates New York $133B AUM 72.99% 1-Year Est. Return

Morgan Stanley New York $1.66T AUM 25.57% 1-Year Est. Return

Weiss Multi-Strategy Advisers's BIIB Position: Q1 2024 in Review

Weiss Multi-Strategy Advisers sold out of Biogen (BIIB) in Q1 2024, closing a stake of 34,696 shares — an estimated $8.98M sold.

Weiss Multi-Strategy Advisers first reported a position in BIIB in Q2 2013 and held it in 26 quarters. The position peaked at $12M in Q1 2023. 954 funds tracked by Wall St. Rank hold BIIB as of Q1 2024.

Weiss Multi-Strategy Advisers reported no remaining Biogen position as of Q1 2024 after selling out during the quarter.
Weiss Multi-Strategy Advisers sold 34,696 Biogen shares in Q1 2024, an estimated $8.98M.
Weiss Multi-Strategy Advisers first reported a position in Biogen in Q2 2013 and held it in 26 quarters.
Weiss Multi-Strategy Advisers's Biogen position peaked at $12M in Q1 2023.
954 funds tracked by Wall St. Rank held Biogen as of Q1 2024.

Based on Weiss Multi-Strategy Advisers's 13F filing for Q1 2024.